跳至主要内容
临床试验/NCT00956280
NCT00956280已完成不适用

Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer

AstraZeneca1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2009年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
100
试验地点
1
主要终点
To analyze the frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC.

研究概览

简要总结

The purpose of this study is to characterize the demographic and clinical aspects, and describe the frequency and type of KRAS mutation in a Brazilian population sample with advanced non-small cell lung cancer (NSCLC).

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histological or cytological confirmation of locally advanced or metastatic Non Small Cell Lung Cancer (IIIB-IV)
  • Tumour sample (block of slides) available for KRAS analysis

排除标准

  • Confirmation of locally advanced or metastatic NSCLC (IIIB-IV) exclusively by cytology, with no tumour sample access.
  • Previous treatment using a MEK inhibitor or any other regimen containing docetaxel (previous treatment with paclitaxel is accepted)

结局指标

主要结局

To analyze the frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC.

时间窗: March 31, 2010

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验